Inotek Pharmaceuticals Corporation

Venture capital investment in the biopharmaceutical industry continues to be massive in terms of both the number of companies raising funds and the size of funding rounds despite the ongoing economic

Initial public offerings in the US by biopharmaceutical firms have dried up since 89bio Inc. launched its IPO on 11 November, but already-public companies have successfully launched very large follo

Turning Point Therapeutics Inc. , which specializes in tyrosine kinase inhibitors (TKIs) for cancer, had one of the best-performing initial public offerings by a biopharmaceutical company this year wh

Moderna Therapeutics LLC continues to confound biopharmaceutical industry observers by staying private, yet raising extremely large amounts of money from investors who want whatever it is that the m